竺淑佳，中国科学院脑科学与智能技术卓越创新中心研究员、博士生导师、研究组组长。获得国家高层次人才青年项目、上海市青年科技英才、上海市启明星、中国神经科学重大进展奖项、中国科学院上海分院杰出青年科技创新人才和中国科学院优秀导师奖等荣誉。她聚焦并系统揭示 ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Schizophrenia is a highly disabling mental disorder, and numerous studies have shown that the hypofunction of the N-methyl-d-aspartate (NMDA) receptor is one of its pathogenic mechanisms.

Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome ...

It is the first and only oral NMDA receptor antagonist to be approved for this use, and the first oral therapy with a new mechanism of action in around 60 years, said Axsome. NMDA antagonist ...